Education
About Us
Working with TipRanks
Follow Us
HBM Holdings Ltd. (HK:2142)
:2142
2142 Stock Chart & Stats
HK$12.08
HK$0.18(8.04%)
At close: 4:00 PM EST
HK$12.08
HK$0.18(8.04%)
Day’s Range― - ―
52-Week RangeHK$5.05 - HK$17.98
Previous CloseN/A
Volume9.30M
Average Volume (3M)8.63M
Market Cap
HK$10.46B
Enterprise ValueHK$1.05B
Total Cash (Recent Filing)HK$320.69M
Total Debt (Recent Filing)HK$64.67M
Price to Earnings (P/E)16.0
Beta1.23
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding895,528,500
10 Day Avg. Volume6,681,047
30 Day Avg. Volume8,634,233
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)1.48
Price to Sales (P/S)4.83
P/FCF Ratio6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.00Price Target Upside49.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginAn 88.2% gross margin indicates durable product-level pricing power or low direct costs. Over months this margin cushion helps absorb operating expenses, supports funding R&D or commercialization, and provides a structural buffer if revenues falter until topline recovery.
Improving LeverageA lower debt-to-equity and a ~58% equity ratio signal stronger capital structure and reduced refinancing risk. For a biotech firm with multi-period projects, improved leverage preserves strategic optionality and lowers interest burden, supporting sustainable investment over months.
Liquid Cushion Vs DebtA relatively high cash stock versus debt provides near-term liquidity to fund operations or clinical/strategic initiatives despite weak operating cash flow. This structural cash buffer reduces immediate solvency risk and affords time to execute longer-term plans.
Bears Say
No Operating Cash FlowLack of operating cash generation and zero FCF are structural red flags: recurring operational deficits force reliance on financing or asset sales. Over months this can limit reinvestment, increase dilution or leverage, and constrain the company's ability to fund sustained development or commercialization.
Declining Profitability MetricsA sharp fall in net margin and negative EBIT/EBITDA point to worsening operating efficiency or higher overheads. If persistent, this erodes the conversion of strong gross margins into shareholder returns, weakens reinvestment capacity, and heightens long-term profitability risk.
Inconsistent Revenue And Declining AssetsVolatile top-line and shrinking asset base reduce visibility and scale economics. Over the medium term, inconsistent revenues hinder planning for development programs and weaken asset utilization, limiting the firm's ability to build durable market position or fund ongoing projects internally.
HBM Holdings Ltd. News
2142 FAQ
What was HBM Holdings Ltd.’s price range in the past 12 months?
HBM Holdings Ltd. lowest stock price was HK$5.05 and its highest was HK$17.98 in the past 12 months.
What is HBM Holdings Ltd.’s market cap?
HBM Holdings Ltd.’s market cap is HK$10.46B.
When is HBM Holdings Ltd.’s upcoming earnings report date?
HBM Holdings Ltd.’s upcoming earnings report date is Apr 01, 2026 which is in 38 days.
How were HBM Holdings Ltd.’s earnings last quarter?
HBM Holdings Ltd. released its earnings results on Aug 27, 2025. The company reported HK$0.7 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.7.
Is HBM Holdings Ltd. overvalued?
According to Wall Street analysts HBM Holdings Ltd.’s price is currently Undervalued.
Does HBM Holdings Ltd. pay dividends?
HBM Holdings Ltd. does not currently pay dividends.
What is HBM Holdings Ltd.’s EPS estimate?
HBM Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HBM Holdings Ltd. have?
HBM Holdings Ltd. has 895,528,500 shares outstanding.
What happened to HBM Holdings Ltd.’s price movement after its last earnings report?
HBM Holdings Ltd. reported an EPS of HK$0.7 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.104%.
Which hedge fund is a major shareholder of HBM Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2142
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HBM Holdings Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$18.00 (49.01% Upside)
HK$18.00 (49.01% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
928.57%
12-Months-Change
Fundamentals
Return on Equity
35.80%
Trailing 12-Months
Asset Growth
74.12%
Trailing 12-Months
Company Description
HBM Holdings Ltd.
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.
2142 Stock 12 Month Forecast
Average Price Target
HK$18.00
▲(49.01% Upside)
Technical Analysis
Alphamab Oncology
―
Lepu Biopharma Co. Ltd. Class H
―
Abbisko Cayman Limited
―
CStone Pharmaceuticals
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---